Aptamer-modified Liposome Development Service
Aptamers are a kind of short single-stranded DNA or RNA oligonucleotides screened from randomized nucleic acid libraries by systematic ligand evolution by exponential enrichment (SELEX). It can bind to target molecules by folding secondary and tertiary structures into specific three-dimensional spatial arrangements. Aptamer-modified liposomes are available from Creative Biolabs for application in biosensors, medical diagnostics, and targeted drug delivery.
Fig.1 Schematic representation of aptamer-modified liposome.
Advantages of Aptamer-modified Liposome
-
Aptamers bind to their targets with great affinity and specificity. They are resistant to organic solvents, as well as temperature and pH changes, making them suitable for a variety of liposome processing methods. Aptamers' lower size allows for more tumor penetration than antibodies, and the process of conjugating to the liposome surface is simpler and more repeatable than with antibodies.
-
Low immunogenicity and minimal adverse reactions
-
Wide range of targets: Amino acids, peptides, small molecules, proteins, cells, viruses, etc.
-
High specificity: Recognize different functional groups of the target molecule as well as its various conformations.
Optional Aptamers for Liposome Surface Modification
Aptamers are categorized into peptide aptamers and nucleic acid aptamers based on their composition. Peptide aptamers are made up of a short sequence of amino acids linked to a stable protein scaffold, whereas nucleic acid aptamers are short strands of RNA or DNA oligonucleotides. Creative Biolabs specializes in the research of aptamer-modified liposomes and provides a variety of aptamer options to ensure you find the best liposome modification for your research.
|
Aptamer
|
Efficacy
|
|
AS1411
|
Promoting the binding of liposomes to nucleolin receptors, which is overexpressed in tumor cells.
|
|
EGFR aptamer
|
Promoting the binding of liposomes to EGFR, which is overexpressed in tumor cells.
|
|
Apt1
|
Promoting the binding of liposomes to CD44, a transmembrane glycoprotein that is overexpressed in solid tumors.
|
|
LC09
|
Promoting the binding of liposomes to osteosarcoma cells.
|
|
A10
|
Promoting the binding of liposomes to prostate-specific membrane antigen (PSMA), which is expressed in prostate cancer cells.
|
|
xPSM-A9
|
|
A15
|
Promoting the specific binding of liposomes to CD133, a membrane protein highly expressed on the surface of prostate cancer cells.
|
|
TSA14
|
Promoting the specific binding of liposomes to Tubo cells, a clonal line established in vitro from BALB-neu T mice with overexpression of HER-2 receptor (HER2/erb-2).
|
|
DAG-NX213
|
Promoting the binding of liposomes to VEGF, which is overexpressed in tumor cells.
|
|
NX 1838
|
|
sgc8
|
Promoting the binding of liposomes to leukemia CCRF-CEM cells.
|
|
IL-4Ra
|
Promotion the binding of liposomes to IL-4Ra receptor, which is expressed in CT26 cancer cells
|
Why Choose Us?
-
Large-scale production capabilities
-
Short preparation cycles
-
Aptamer-based conjugate services for targeted drug delivery: Aptamer-drug conjugates, aptamer-modified liposome, and other nanoparticle
With our expertise in covalent and non-covalent conjugation of aptamers, Creative Biolabs can provide customized aptamer-modified liposome services for your specific needs. In addition, Additionally, you can contact us to learn more about aptamer-drug conjugates and aptamer-modified nanoparticles. Trust us to leverage our knowledge and experience in aptamers to enhance the precision and efficiency of your research and development projects.
For Research Use Only. Not For Clinical Use
